US Stock MarketDetailed Quotes
THAR Tharimmune
- 2.585
- +0.025+0.98%
Trading Nov 25 13:49 ET
3.84MMarket Cap0.04P/E (TTM)
2.650High2.510Low56.48KVolume2.570Open2.560Pre Close146.47KTurnover3.87%Turnover RatioLossP/E (Static)1.49MShares11.47552wk High1.27P/B3.77MFloat Cap1.83552wk Low--Dividend TTM1.46MShs Float1590.000Historical High--Div YieldTTM5.47%Amplitude1.835Historical Low2.593Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Tharimmune Stock Forum
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease
Tharimmune (NASDAQ:THAR) presented Phase 1 clinical data for TH104 at AASLD The Liver Meeting 2024. The trial evaluated TH104 transmucosal buccal film in patients with chronic liver disease (CLD) for chronic pruritus treatment.
The study showed significant correlation between blood levels and symptom relief, with a correlation coeff...
Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics
Tharimmune (NASDAQ:THAR) has been granted a European patent for biodegradable polymeric nanoparticles designed to deliver therapeutic antibodies and peptides. The technology aims to enhance drug delivery by improving stability and reducing systemic side effects, particularly in cancer therapies. The nanoparticles feature tunable size, non-toxic profiles, and extended drug hal...
No comment yet